Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Date publication

septembre 2025

Journal

Neurology(R) neuroimmunology & neuroinflammation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG, Patti F, Kleiter I, Palace J, De Seze J, Evans R, Blondeau K, Klingelschmitt G, Vodopivec I, Rahim M, Yamamura T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40743487

Résumé

Satralizumab (SAT), an interleukin-6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo (PBO) with a favorable safety profile in patients with neuromyelitis optica spectrum disorder (NMOSD) in 2 pivotal phase 3 trials, SAkuraSky and SAkuraStar. We evaluated the long-term safety and efficacy of SAT in patients with NMOSD in the single-arm, open-label, rollover study SAkuraMoon.

Mots clés

Humans, Neuromyelitis Optica, drug therapy, Female, Adult, Male, Middle Aged, Double-Blind Method, Antibodies, Monoclonal, Humanized, adverse effects, Immunologic Factors, adverse effects

Référence

Neurol Neuroimmunol Neuroinflamm. 2025 09;12(5):e200450